ClinConnect ClinConnect Logo
Search / Trial NCT06441357

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

Launched by TANG-DU HOSPITAL · May 28, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Ecv, Invasion, Lung Adenocarcinoma, Dect

ClinConnect Summary

This clinical trial is studying a new way to help doctors determine how serious lung adenocarcinoma, a type of lung cancer, is by using a special imaging technique called dual energy computed tomography (DECT). The main goal is to see if measuring something called the extracellular volume (ECV) can help tell the difference between less serious, precancerous conditions and early-stage lung cancer. This information could guide doctors in making better decisions about whether surgery is needed and how to plan that surgery.

To participate in this study, individuals must be at least 18 years old and have small lung nodules (growths in the lung) that are 3 centimeters or smaller, confirmed to be lung adenocarcinoma. Participants should not have a history of other types of cancer or have undergone treatments like chemotherapy or radiation before the DECT scan. During the study, participants will undergo a contrast-enhanced DECT scan, which involves a special dye that helps improve the images of the lungs. The trial is currently recruiting participants, and it's important to note that individuals with certain allergies or health conditions may not be eligible. This research could lead to better ways to diagnose and treat lung cancer in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patients older than 18 years old with pulmonary nodules (diameter≤3 cm).
  • pathologically confirmed as lung adenocarcinoma.
  • without history of other malignancies.
  • accurate hematocrit within 1 week before contrast enhanced dual energy CT examination.
  • Exclusion Criteria:
  • with a history of allergy to iodine contrast agents and other reasons who are unable to complete the examination.
  • without histopathology of invasion stage, such as AAH, AIS, MIA and IAC.
  • history of chemotherapy, radiotherapy, or other anti-tumor therapy before contrast enhanced dual energy CT.
  • poor image quality.
  • contrast enhanced dual energy CT scans ≥ 4 weeks before surgery.

About Tang Du Hospital

Tang-Du Hospital, affiliated with the Fourth Military Medical University, is a leading medical institution in China renowned for its comprehensive healthcare services and advanced research capabilities. As a prominent clinical trial sponsor, Tang-Du Hospital is committed to advancing medical science through rigorous clinical research. The hospital leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct innovative studies that aim to improve patient outcomes and contribute to the global medical community. With a strong emphasis on ethical standards and patient safety, Tang-Du Hospital is dedicated to fostering collaborations that enhance the development of new therapies and medical technologies.

Locations

Xi'an, Shaanxi, China

Patients applied

0 patients applied

Trial Officials

Cui Guangbin

Study Chair

ang-Du Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported